第702回千葉医学会例会・第1内科教室同門会例会 17.

Description of patients included at each time point in each of the development and validation samples. (DOC 37 kb

第673回千葉医学会整形外科例会 28.

Description of patients included at each time point in each of the development and validation samples. (DOC 37 kb

Additional file 1: of Cost-effectiveness of a cardiac output-guided haemodynamic therapy algorithm in high-risk patients undergoing major gastrointestinal surgery

Supplementary data describing costs and the findings of sub-group analyses and sensitivity analyses. The additional file 1 includes supplementary information on unit costs of resources, 6 months results (hospital costs, sub-group results, cost-effectiveness acceptability curves), Kaplan-Meier survival curves and parametric extrapolation of survival beyond trial period, results of sensitivity analysis and populationexpected value of perfect information

Additional file 3: of Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models

Differential protein expression. Log fold changes of differentially expressed proteins over 14 days are shown in 4 worksheets, each for a xenograft-treatment condition: carboplatin treated OV1002; carboplatin treated HOX424; carboplatin-paclitaxel treated OV1002; carboplatin-paclitaxel treated HOX424. (XLS 57 kb

Additional file 2: of FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): a multicentre pilot randomised controlled trial of high-flow nasal cannula therapy versus continuous positive airway pressure in paediatric critical care

Figure S2. Study algorithm for the management of patients randomised to continuous positive airway pressure. (PDF 156 kb

Additional file 4: of FIRST-line support for Assistance in Breathing in Children (FIRST-ABC): a multicentre pilot randomised controlled trial of high-flow nasal cannula therapy versus continuous positive airway pressure in paediatric critical care

Figure S3. Crossover and escalation to invasive ventilation within 72 h of starting the randomised treatment by treatment group. (PDF 50 kb

Additional file 5: Table S4. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units

Final risk models at admission, 24 h and end of calendar day 3. (DOC 44 kb

Irish National ICU Audit Annual Report 2017

By the end of 2017, the Irish National Intensive Care Unit Audit (INICUA) run by the National Office of Clinical Audit (NOCA) covered 58% of Intensive Care Unit (ICU) activity in adult Health Service Executive (HSE) funded hospitals (12 Units in nine hospitals) and all ICU activity in both specialist paediatric hospitals in the Republic of Ireland (ROI).</div

Additional file 1: Table S1. of Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units

Site of Candida invasive fungal disease (N = 359). (DOC 31 kb

1,2,4-Triazolo-[1,5‑<i>a</i>]pyridine HIF Prolylhydroxylase Domain‑1 (PHD-1) Inhibitors With a Novel Monodentate Binding Interaction

Herein we describe the identification of 4-{[1,2,4]­triazolo­[1,5-<i>a</i>]­pyridin-5-yl}­benzonitrile-based inhibitors of the hypoxia-inducible factor prolylhydroxylase domain-1 (PHD-1) enzyme. These inhibitors were shown to possess a novel binding mode by X-ray crystallography, in which the triazolo N1 atom coordinates in a hitherto unreported monodentate interaction with the active site Fe²⁺ ion, while the benzonitrile group accepts a hydrogen-bonding interaction from the side chain residue of Asn315. Further optimization led to potent PHD-1 inhibitors with good physicochemical and pharmacokinetic properties